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CD4 Th1 type immunity is implicated in resistance to global
infectious diseases. To improve the efficacy of T cell immunity
induced by human immunodeficiency virus (HIV) vaccines, we are
developing a protein-based approach that directly harnesses the
function of dendritic cells (DCs) in intact lymphoid tissues. Vaccine
proteins are selectively delivered to DCs by antibodies to DEC-205/
CD205, a receptor for antigen presentation. We find that polyri-
boinosinic:polyribocytidylic acid (poly IC) independently serves as
an adjuvant to allow a DC-targeted protein to induce protective
CD4 T cell responses at a mucosal surface, the airway. After two
doses of DEC-targeted, HIV gag p24 along with poly IC, responder
CD4 T cells have qualitative features that have been correlated
with protective function. The T cells simultaneously make IFN-,
tumor necrosis factor (TNF)-, and IL-2, and in high amounts for
prolonged periods. The T cells also proliferate and continue to
secrete IFN- in response to HIV gag p24. The adjuvant role of poly
IC requires Toll-like receptor (TLR) 3 and melanoma differentiation-
associated gene-5 (MDA5) receptors, but its analog poly IC12U
requires only TLR3. We suggest that poly IC be tested as an
adjuvant with DC-targeted vaccines to induce numerous multifunc-
tional CD4 Th1 cells with proliferative capacity.
HIV  gag  adjuvant  MDA5  TLR3
Cell mediated immunity is implicated in resistance to globalinfectious diseases like HIV, malaria, and tuberculosis (1–3).
CD4 Th1 helper cells are a key component of this immunity (4).
They produce large amounts of IFN- and TNF- (5), exert
cytolytic activity on major histocompatibility complex (MHC) class
II targets (6), and sustain functional CD8 T memory cells (7, 8).
HIV-specific CD4 T cells that produce IL-2 can restore prolifer-
ation of antigen-specific CD8 T cells in vitro (9). Further, HIV-
specific CD4 T cells that produce multiple cytokines such as IFN-
and IL-2 (10–12), or proliferate and secrete IFN- upon encounter
with HIV antigens (13), are reported to be associated with a better
clinical outcome, whereas higher numbers of CD4 memory T cells
correlate with superior protection by SIV vaccines in monkeys (14).
Therefore, effective vaccine development requires an understand-
ing of how to generate CD4 T cells in sufficient quantity and
quality to provide protective immunity.
DCs are antigen presenting cells that induce strong T cell-based
responses (15). For example, when a subset of DCs that express the
endocytic receptor DEC-205 (16) is loaded with antigen ex vivo and
reinfused into mice, the DCs expand antigen-specific helper T cells
to primarily produce IFN- (17, 18). In vivo, DEC-205 expressing
DCs (DEC DCs) mediate antigen presentation on both MHC
class I and II products, leading to clonal expansion of CD8 and
CD4 T cells respectively (19). We are developing an approach that
targets antigens directly to DCs in situ using the DEC receptor
(20–24), which is expressed on DCs in the T cell areas (25),
particularly a subset (26) that often expresses CD8 (27). Delivery of
vaccine proteins engineered into -DEC mAbs greatly enhances
the efficiency of antigen presentation (20, 21, 23, 24) and allows
protein-based vaccines to induce large numbers of Th1 type CD4
T cells (22–24), as well as CD4 dependent protection to challenge
with recombinant vaccinia virus (23).
Productive immune responses require both antigen uptake and
DC maturation, because in the absence of maturation, DCs can
induce T cell tolerance (20, 21). DC maturation can be achieved
with adjuvants, including chemically defined ligands for pattern
recognition receptors, such as the TLRs (28, 29). For example,
HIV-specific, CD4 and CD8 immunity in mice (30) and monkeys
can be induced by conjugating TLR7/8 ligand to HIV gag p41,
whereas unconjugated HIV gag p41 is poorly immunogenic (31,
32). However, ligands for pattern recognition receptors have not
been evaluated as adjuvants with DC-targeted HIV vaccines.
In our prior studies, we administered -DEC fusion mAb to-
gether with a combination of an agonistic -CD40-mAb and poly
IC as a DC maturation stimulus (22–24). Poly IC is recognized by
endosomal TLR3 expressed by DEC DCs (33) and by MDA5
cytosolic receptors (34). Poly IC has been tested as a single
therapeutic agent at high doses in patients with malignant disease
(35–37), and it acts as an adjuvant for antibody immunity (38, 39).
Here, we show that poly IC alone is an effective adjuvant for a
DC-targeted vaccine to yield CD4 T cell immunity that is quan-
titatively and qualitatively robust and also protective in a lung
infection model.
Results
Poly IC Is an Adjuvant for Strong CD4 T Cell Responses to DEC-
Targeted HIV gag p24. To examine the adjuvant properties of poly
IC and monophosphoryl lipid A (MPLA) we measured serum
cytokine responses. Poly IC (50 g) induced more IL-6 relative to
MPLA [supporting information (SI) Fig. 6A] and also elicited
TNF- and IFN-. To evaluate the efficacy of these compounds as
adjuvants for HIV gag-specific, CD4 T cell responses, we admin-
istered each with -DEC-p24 mAb twice i.p. over 4 wk. One week
after the final injection, IFN- secretion was monitored in response
to HIV gag p24 peptides by multicolor flow cytometry using the
gating strategy shown in SI Fig. 7. Poly IC was a superior adjuvant
to MPLA for inducing strong CD4 T cell responses, achieving
frequencies of IFN- secreting T cells that corresponded to 0.5–6%
of total CD3 CD4 T cells (SI Fig. 6B). However, poly IC was
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needed during both priming and booster doses of vaccine (data not
shown).
-DEC-gag Plus Poly IC Elicits Multifunctional and High Cytokine-
Secreting CD4 T Cells. To assess the quality of CD4 T cells induced
with poly IC, we injected mice with -DEC-p24 and graded doses
of poly IC over 6 wk. One group received -DEC-p24 and poly IC
only at the time of boost. Two weeks after the boost, the frequency
of gag-specific, CD4 T cells producing IL-2, IFN-, or TNF- was
greatest with two doses of -DEC-p24 mAb and 50 g of poly IC
(Fig. 1A and SI Fig. 8A).
We then examined the capacity of the individual gag-specific T
cells to secrete multiple cytokines. Such multifunctional T cells
elicited by immunization prospectively correlate with protection in
a mouse model of Leishmania major infection (5) and are found
retrospectively to be increased in HIV infected individuals who
have a better clinical outcome (10, 12). Fourteen days after
prime-boost immunization with -DEC-p24 and 50 g of poly IC,
50% of the gag-specific CD4 T cells produced all three cyto-
kines, IFN-, IL-2, and TNF- (Fig. 1B and SI Fig. 8B). The total
frequencies of cytokine producers was less if we used two doses of
-DEC-p24 and 10 g of poly IC, or a single immunization with
-DEC-p24 and 50 g of poly IC (Fig. 1B).
We also assessed the amount of each cytokine (median fluores-
cence intensity or MFI) made by gag-responsive cells, because this
parameter correlates with protective CD4 immunity in the L.
major model (5). We found that the MFI of cells producing 3
cytokines were higher for IFN-, IL-2, and TNF- than the MFI of
cells producing two cytokines or one cytokine (Fig. 1C). Therefore,
the effector CD4 T cells induced with -DEC-p24 and poly IC
have features, like multifunctionality and high cytokine production,
that are currently associated with superior Th1 immunity.
CD4 Effector T Cells Persist for Several Weeks After Prime-Boost
Immunization. To assess the duration of HIV gag-specific cytokine-
producing (‘‘effector’’) CD4 T cells after prime-boost immuniza-
tion with -DEC-p24 plus poly IC, we analyzed mice 2 and 7 wk
after the boost. As summarized for three experiments each in
C57BL/6 and BALB/c mice, specific effector CD4 T cells persisted
at least 7 wk, but decreased from week 2 to 7 (SI Fig. 9). The
percentage of cells producing all three cytokines (IFN-, TNF-,
IL-2) remained stable from week 2 to 7 after the boost (data not
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Fig. 1. Properties of HIV gag-specific CD4 T cells after prime-boost immunization with -DEC-p24 and poly IC. C57BL/6 mice were injected s.c. with 5 g of -DEC-p24
and 2, 10, or 50 g of poly IC or PBS, and boosted with the same conditions 6 wk later. One other group received 5 g of -DEC-p24 and 50 g of poly IC once at the
time of the boost. Two weeks later, HIV gag-specific, CD3 CD4, splenic T cells were analyzed for IFN--, IL-2-, and TNF--secretion (A), percentage of CD4 T cells
expressing each of seven possible combinations of IFN-, TNF-, and IL-2 (B), and IFN-, TNF-, and IL-2 MFIs of gag-specific cells expressing 3, 2, or 1 cytokines after
prime-boost with -DEC-p24 plus 50 g of poly IC (C). Data are representative of two experiments with two mice pooled in each.









































is similar to that reported using Leishmania protein administered
with CpG (5). Injection of two doses of control Ig-p24 or one dose
of -DEC-p24 plus 50 g of poly IC resulted in lower frequencies
of cytokine-producing CD4 T cells, which declined at week 2 to 7
(SI Fig. 9). Thus, prime-boost immunization induces high frequen-
cies of durable multifunctional CD4 T cells.
Prime-Boost Immunization with -DEC-gag and Poly IC Induces Pro-
liferating CD4 T Cells. CD4 Th1 cell proliferation and IFN-
production are reported to be associated with low HIV-1 RNA and
proviral DNA loads (13). To determine whether these features
could be induced by a DC-targeted vaccine, splenocytes were
labeled with carboxyfluorescein succinimidyl ester (CFSE) to fol-
low the successive halving of CFSE/cell with each division. Two wk
after the boost, CD4 T cells were cultured for 3 days and
challenged with p24 peptides. The T cells responded by prolifera-
tion and IFN- formation, specifically to gag p24 in the vaccine, and
not the control gag p17 peptide mix. Fewer responding CD4 T
cells were seen with two doses of -DEC-p24 plus 10 or 2 g of poly
IC or one dose of -DEC-p24 plus 50 g of poly IC (Fig. 2A).
To assess the persistence of proliferative, HIV gag-specific CD4
T cells after prime-boost immunization, we did three experiments
each in C57BL/6 and BALB/c mice and found that proliferative
CD4 T cells persisted at least 7 wk but decreased from week 2 to
7 (Fig. 2B). Only low frequencies of proliferating CD4 T cells were
identified after two doses of control Ig-p24 or one dose of -DEC-
p24 plus poly IC, and only at 2 but not 7 weeks after vaccination.
Therefore, a prime boost with -DEC-p24 and 50 g of poly IC
induces both long-lived IFN- secreting and proliferating CD4 T
cells.
Poly IC also Serves as an Adjuvant for CD4 T Cell Responses to
-DEC-nef. To extend the concept of directed delivery of antigens to
DCs in situ to other HIV antigens, we engineered the nef protein
into the -DEC-205 heavy chain. The fusion mAbs were expressed
and contained heavy chains of 70 kDa as opposed to 50 kDa for
unmodified mouse IgG1 (SI Fig. 10). When BALB/c mice were
immunized with two doses of -DEC-nef plus poly IC, CD4 T cells
became responsive to one nef peptide pool; in contrast, two doses
of ‘‘empty’’ -DEC-205 mAb plus poly IC did not immunize (Fig.
3A). This strategy also elicited proliferating IFN- producing CD4
T cells (Fig. 3B), indicating good quantity and quality CD4 T cell
responses to HIV nef as well as gag.
Prime-Boost Immunization with -DEC-gag and Poly IC Elicits Protec-
tion at a Mucosal Surface. To determine if poly IC acts as an adjuvant
for long lasting protective immunity at a mucosal surface, the lung,
we challenged vaccinated BALB/c and C57BL/6 mice intranasally
(i.n.) with recombinant vaccinia-gag virus 6–8 wk after prime-boost
immunization with -DEC-gag and poly IC. In initial protection
experiments, we verified that a dose of 50 g of poly IC gave optimal
protection (SI Fig. 11A). The results from three experiments each
in BALB/c and C57BL/6 mice show that mice injected with PBS lost
weight and developed high titers of virus in the lung ( 108 PFU/ml)
over 6–7 days (Fig. 4A). By two criteria, reduced weight loss and
reduced growth of virus, two doses of -DEC-p24 and 50 g of poly
IC provided better protection relative to two doses of control Ig-p24
or one dose of -DEC-p24 plus poly IC.
As previously described, CD4 T cell depletion from vaccinated
mice before the challenge with vaccinia-gag ablated protection (23)
(SI Fig. 11B). In addition, DEC expression was essential because
DEC/ mice failed to be protected (Fig. 4B). However, TLR3/
mice were fully protected to vaccinia-gag when immunized with two
doses of -DEC-p41 and poly IC (Fig. 4B), indicating that TLR3
was not essential for protection with poly IC adjuvant.
TLR3 Dependent Immunity to DC-Targeted HIV gag Vaccine and Poly
IC12U. We also examined the poly IC analog poly IC12U (trade name
Ampligen) as an adjuvant, because poly IC12U exhibits minimal
Fig. 2. Prime-boost immunization with -DEC-p24 and poly IC induces long-lived IFN--secreting and proliferating CD4 T cells. (A) As in Fig. 1, but 2 wk after
boosting, bulk splenocytes were CFSE-labeled and stimulated with -CD28 and gag p24 peptide mix, control gag p17 peptide mix, or -CD3 for 3 days, whereupon
the cells were restimulated for 6 h with HIV gag p24 peptides to detect IFN- in proliferated CFSElow, CD3CD4 T cells. Data are the percentage of IFN- or IFN-
CD3CD4 proliferating T cells (Top Left and Bottom Left, respectively) from one of two similar experiments with two mice pooled in each. (B) As in A, but mean 
SD of the frequencies of IFN--producing and proliferating CD3CD4 T cells in three experiments in BALB/c or C57BL/6 mice immunized twice with the indicated
vaccines at a 6-wk interval, 2 and 7 wk after boost (except control Ig-p24; n  2 in C57BL/6 and n  1 in BALB/c mice).

































toxicity even at high doses but shares immunomodulatory proper-
ties with poly IC (40, 41). CxB6 F1 mice were injected with two
doses of -DEC-p24 mAb plus increasing doses of poly IC or poly
IC12U, and we monitored the proliferative capacity of CD3CD4
T cells in response to HIV gag p24 peptides 1 wk after boosting.
Both forms of poly IC induced CD4 T cell responses that were
dose-dependent, although the immune response induced by poly IC
was greater than with poly IC12U (Fig. 5A).
To determine the pattern recognition receptors required by poly
IC and poly IC12U, we tested wild-type, TLR3/ and MDA5/
mice. Poly IC had some adjuvant activity in TLR3/ mice, whereas
poly IC12U could not elicit CD4 IFN- secreting T cells in these
animals (Fig. 5B). Both adjuvants elicited responses in MDA5/
mice. Taken together the data indicate that TLR3 is essential for the
adjuvant role of poly IC12U, but poly IC may require both TLR3 and
the cytosolic sensor MDA5.
Discussion
Dendritic cells are potent inducers of T cell-mediated immunity and
are therefore attractive targets to improve vaccine efficacy. As an
example, when vaccine proteins are selectively delivered by mAbs
to DC endocytic receptors, antigen presentation and immune
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Fig. 3. -DEC-nef and poly IC induces nef-specific CD4 T cell immunity. BALB/c mice were injected twice i.p. with 5 g of -DEC-nef or unconjugated -DEC mAb
and 50 g of poly IC at a 6-wk interval. Nef-specific T cells were analyzed a week after boosting. (A) IFN- in spleen CD3CD4 T cells in response to HIV nef peptide
mix, different nef peptide pools, or nonreactive peptide mix. (B) CFSE-labeled bulk splenocytes were stimulated with -CD28 and nef peptide mix, nonreactive peptide
mix or -CD3 for 3 days, whereupon the cells were restimulated with HIV nef peptides to detect IFN- in proliferated CFSElow, CD3CD4 T cells. Shown is the percentage
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Fig. 4. Prime-boost immunization with 5 g of -DEC-gag and 50 g of poly IC provides protective immunity to airway challenge with vaccinia-gag virus. (A)
Average weight loss (Left) and lung virus titers (Right) as a mean  SD after challenge from six experiments, three each in BALB/c and C57BL/6 mice (except control
Ig-p24; n  2 in BALB/c). Mice were primed and boosted at a 6-wk interval with the indicated vaccines. Another group was immunized with -DEC-p24 and poly
IC at the time of the boost only. Six to eight weeks after boost, mice were challenged i.n. with 5  104 PFU vaccinia-gag. (B) As in A, but C57BL/6, DEC-205/,
or TLR3/ mice were immunized with -DEC-p41 and challenged with vaccinia-gag. Data are one of two similar experiments. Data are average body weight
(Left) or vaccinia plaque-forming titers in lung (Right) as mean  SD (n  5).









































responses develop with much greater efficacy relative to nontar-
geted antigen. One receptor under study is DEC or CD205, which
is expressed on DCs in the T cell areas (25, 42). Previously, we
immunized mice with -DEC-HIV gag p24 fusion mAb together
with a combination of agonistic -CD40-mAb and poly IC as the
adjuvant (23), and we studied the primary CD4 T cell response to
gag. Here, we used poly IC alone as a DC maturation stimulus, as
a preclinical model for future proof of concept studies in monkeys
and humans, and we studied several features of the quality of CD4
T cell immunity including memory. Our data reveal the potential of
poly IC to serve as an adjuvant using a protein based vaccine that
directly targets DCs and elicits long-lived and protective Th1 CD4
T cells of superior quality and quantity.
The CD4 T cell response with poly IC as an adjuvant was
multifunctional, i.e., the T cells produced multiple cytokines such as
IFN-, TNF-, and IL-2, and in high amounts. We also found that
the DEC-targeted vaccine induced high frequencies of IFN--
producing and proliferating CD4 T cells, a feature that to date is
unique to this vaccine approach. Increased frequencies of multi-
functional CD4 T cells elicited by immunization correlate with
better protection in the L. major model (5). Further, they are found
retrospectively to be increased in HIV infected individuals who
have a better clinical outcome (10, 12).
Another interesting consequence of DC-targeted HIV gag p24
was the induction of long-lasting protective CD4 Th1 T cell
immunity to vaccinia-gag. IFN- resists vaccinia infection (43), and
CD4 Th1 cells lyse cytomegalovirus-infected MHC II targets (6);
both features may contribute to resistance induced by DEC tar-
geted proteins together with poly IC.
Poly IC can be recognized by TLR3 endosomal (33) and MDA5
cytosolic receptors (34). We found that both TLR3 and MDA5
contributed to the adjuvant action and protective immunity with
poly IC. In contrast, TLR3 was exclusively needed for the adjuvant
role of poly IC12U (44).
Interestingly, we observed only weak CD8 T cell responses to 2
doses of poly IC adjuvanted, DC-targeted vaccine (data not shown).
This result is surprising, given evidence that DEC DCs efficiently
cross-present ovalbumin to CD8 T cells, particularly ovalbumin
delivered within -DEC mAbs (21). In addition, poly IC induces
type I interferons, which promote cross-presentation by DCs (45)
and survival of CD8 T cells (46). More research is required to
evaluate whether the CD8 T cell response induced by DEC-
targeted vaccine can be improved with different DC stimuli or
different vaccine formulations.
Although poly IC has been used as an adjuvant to enhance the
immunogenicity to a vaccine protein in mice (38), its ability to
induce CD4 T cell responses that are also protective has not been
shown before. Targeting of poly IC-adjuvanted vaccine protein to
DEC DCs should favor the kind of Th1 CD4 T cell immunity
now implicated in resistance to many global infectious diseases.
Materials and Methods
Mice. C57BL/6 (B6), BALB/c, and CxB6 F1 were from Harlan. Mice deleted for TLR3,
MDA5 and DEC-205 genes were kindly provided by S. Akira (Osaka University,
Osaka, Japan), M. Colonna (Washington University, St. Louis, MO), and M. Nus-
senzweig (The Rockefeller University, New York, NY). Mice were maintained
under specific pathogen-free conditions and used at 7–8 wk of age according to
Institutional Animal Care and Use guidelines.
Fusion HIV Protein mAbs. HIV gag-p24, HIV gag-p41, and unconjugated -DEC-
205 mAbs were prepared as described in ref. 23. To clone HIV nef into the COOH
terminus of -DEC-205 mAb heavy chain (20), the nef sequence was amplified by
overlapping PCR from a CCR5-tropic primary virus classified as a subtype C/B
recombinant. Fusion HIV nef mAbs were expressed by transient transfection
(calcium-phosphate) as for HIV gag fusion mAbs (23). All mAbs were character-
ized by SDS/PAGE and Western blotting using HRP sheep anti-mouse IgG (GE
Healthcare, Buckinghamshire, U.K.) or HRP-anti-gag p24 (ImmunoDiagnostics,
Woburn, MA). mAbs binding was verified on CHO cells stably transfected with
mouse DEC-205 by FACS using PE-conjugated goat anti-mouse IgG (Jackson
ImmunoResearch, West Grove, PA). All mAbs were endotoxin-free in Limulus
Amebocyte Lysate assay, QCL-1000 (Cambrex, Walkersville, MD).
HIV Peptides. A library of overlapping (staggered by 4 aa) 15-mer peptides
spanning the entire HIV gag p17, p24 or nef proteins were synthesized by the
Proteomics Resource Center (The Rockefeller University). The 30-member gag
p17 and 60-member gag p24 libraries were resuspended at 1 mg/ml of each
peptide in100%DMSO,whereasthenew50-membernef librarywasdividedinto
four pools of 12–13 peptides each, spanning amino acids 1–58 (pool 1), amino
acids 59–106 (pool 2), amino acids 107–152 (pool 3), and amino acids 153–204
(pool 4) of HIV nef.
Immunizations. Mice were injected once or twice i.p. or s.c. in the hind footpads
at 4- to 6-wk intervals with fusion mAb together with adjuvant, which was poly
IC (2, 10, or 50 g; InVivoGen, San Diego, CA), poly IC12U (10, 50, or 250 g;
Ampligen Hemispherx, Philadelphia, PA), or 30 g of MPLA (InVivoGen).
In Vivo Cytokine Analysis. Mice were injected i.p. with 50 g of poly IC or 30 g
of MPLA and serum was collected at the indicated times to measure TNF- and
IL-6 by ELISA (eBioscience, San Diego, CA) and IFN- by an ELISA kit from R&D
Systems (Minneapolis, MN).
Assays for HIV-Specific Immune T Cells. Bulk splenocytes were either restimu-






































Fig. 5. Poly IC12U acts as an adjuvant for CD4 T cell immunity to -DEC-p24 vaccine in a TLR3-dependent manner. (A) CxB6 F1 mice were injected i.p. with 5
g of -DEC-p24 plus graded doses of poly IC (InVivoGen) or poly IC12U (Ampligen) or PBS, and boosted with the same conditions 6 wk later. The percentage
of IFN--producing and proliferating CD3CD4 T cells in response to HIV gag p17 or p24 mix 1 wk after boost are shown as mean  SD (n  4 mice). (B)
IFN--secretion in response to HIV gag p24 peptides by CD4 splenocytes in wild-type, TLR3/, and MDA5/ mice immunized with two doses of -DEC-p24 plus
50 g of poly IC (InVivoGen) or 250 g of poly IC12U (Ampligen). Data are one of two similar experiments with two mice in each.

































peptide mix (peptides at 1 g/ml), in the presence of 2 g/ml costimulatory
-CD28 (clone 37.51) for 6 h at 37°C, adding Brefeldin A (BFA) (10 g/ml; Sigma–
Aldrich, St. Louis, MO) for the last 5 h to allow accumulation of intracellular
cytokines. Cells were washed, incubated 10 min at 4°C with 2.4G2 mAb to block
Fc receptors, washed, and stained with Live/Dead Fixable Aqua viability dye
(Invitrogen, Carlsbad, CA), Pacific blue-conjugated anti-CD3, PerCP-conjugated
anti-CD4, and APC-Cy7-conjugated anti-CD8 (BD Biosciences, San Diego, CA)
mAbs for 20 min at 4°C. Cells were permeabilized (Cytofix/Cytoperm Plus; BD
Biosciences) and stained with Alexa Fluor 700-conjugated -IFN-, APC-
conjugated -IL-2, and Alexa Fluor 488-conjugated -TNF- mAbs for 15 min at
room temperature (BD Biosciences), resuspended in BD stabilizing fixative, and
100,000 live-CD3 cells were acquired on a BD LSR II flow cytometer. Data were
analyzed with FlowJo Software (Tree Star, Inc., San Carlos, CA) and Spice 4.0 (M.
Roederer, National Institutes of Health). To assess proliferation of primed T cells,
bulk splenocytes were labeled with CFSE (107 cells per ml, 1 M, 10 min, 37°C;
Molecular Probes, Eugene, OR) and cultured with -CD28 and either HIV gag p24,
HIV nef peptides, nonreactive peptide mix or -CD3 (0.1 g/ml; positive control)
in 96-well, round-bottom plates. After 3 days of culture, samples were restimu-
lated for 6 h with p24 or nef peptides and -CD28, adding BFA at 10 g/ml for the
last 5 h. The cells were stained with PerCP-conjugated -CD3 and PE-conjugated
-CD4 as above, permeabilized, stained with APC-conjugated -IFN- mAb for 15
min at room temperature (BD Biosciences), and acquired on a FACSCalibur with
data analysis in FlowJo Software (Tree Star), collecting 40,000 high-CD3 events.
Protection to Airway Challenge with Recombinant Vaccinia-gag Virus. We
applied 5  104 PFU i.n. to groups of four to five nembutal-anesthetized mice. In
some cases, vaccinated C57BL/6 mice were depleted of CD4 T cells by injecting
100 g of GK 1.5 mAb 1–3 days before challenge. To assess protection, we
monitored body weights daily for 6–7 days and then harvested lungs to measure
PFU on CV-1 cell monolayers.
Statistical Analysis. All comparisons between vaccine groups used a two-tailed
Student’s t test to compare the differences between means and standard devi-
ation of the experimental groups shown in the figures. Analysis was performed
with a Prism 3 program (Graphpad Software Inc., San Diego, CA).
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